Autism Spectrum Disorder Therapeutics Market Report and Forecast 2025-2034
Description
The autism spectrum disorder therapeutics market size attained a value of USD 2.11 Billion in 2024, driven by the increasing research and development aided by the government and industrial players, and a growing pipeline of autism spectrum disorder drugs across the 8 major markets. The market is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to attain a value of USD 3.81 Billion by 2034.
Autism Spectrum Disorder Therapeutics Market Overview
Autism spectrum disorder (ASD) is a neurological development disability characterized by conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. This neurological and developmental disorder can begin in infancy and last throughout adulthood throughout a person’s life. It can be diagnosed based on behavioural patterns. ASD treatments are focused on reducing the factors that interfere with an individual’s orderly functioning. Some of the drugs approved by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.
Autism Spectrum Disorder Therapeutics Market Growth Drivers
Rising Number of Pipeline Drugs Expected to Propel Market Growth
The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1. The trials will allow the application of the company’s precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.
Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand
In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd., announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmide™ (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD). The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.
Autism Spectrum Disorder Therapeutics Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Advancement in Diagnostic Tools
The rising advancement in diagnostic tools and techniques that enable earlier detection of autism spectrum disorder is a major trend that stimulates the demand for the therapeutics market. Further, increased implementation of screening programs, particularly in schools and pediatric practices, is resulting in early diagnosis and timely intervention._x000D_
Development of Behavioral Therapies
The rising focus on the development of behavioral therapies is a major market trend. Behavioral therapies including applied behavior analysis (ABA) and cognitive-behavioral therapy (CBT) are increasingly being integrated into treatment plans and are poised to boost the autism spectrum disorder therapeutics market share._x000D_
Rising Adoption of Telemedicine and Digital Health Platforms
The market is experiencing a rising adoption of telemedicine and digital health platforms which has expanded access to care for individuals with autism spectrum disorder, particularly those living in underserved areas. The increasing remote access to care is expected to augment the market demand in the forecast period._x000D_
Increased Awareness Campaigns
Increased public campaigns and advocacy efforts are leading to greater acceptance of autism spectrum disorder, which is resulting in early diagnosis of the affected patients. In addition, advocacy groups and several foundations are offering considerable funding and support for ASD research and treatment development, which directly impacts the market dynamics.
Autism Spectrum Disorder Therapeutics Market Segmentation
Autism Spectrum Disorder Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type Germany
France
Italy
Spain
United Kingdom
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on treatment, the market is segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others. These medications help in treating different aspects associated with the disorder, ranging from managing core symptoms to treating comorbid conditions. The antipsychotic drugs segment covers a significant market share owing to their efficacy in managing severe behavioral issues such as aggression, irritability, and self-injurious behaviors, which are common in individuals affected by the condition.
Autism Spectrum Disorder Therapeutics Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to hold a significant share of the market during the forecast period, supported by the increased number of autism spectrum disorder cases in the region. The market is also supported by the presence of a favorable regulatory environment. For example, the United States Food and Drug Administration (FDA) authorized the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD) in 2021.
The region is also characterised by research and development in the field of autism spectrum disorder which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the United States, supports research focused on the treatment of autism spectrum disorder and related disorders.
Leading Players in the Autism Spectrum Disorder Therapeutics Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company AbbVie Inc. is involved in research and development (R&D) efforts to create medications for autism spectrum disorder. The company's robust portfolio of neurological and psychiatric therapeutics and its strong R&D capabilities position it as a significant player in the market.
Jazz Pharmaceuticals
This global biopharmaceutical company specializes in developing treatments in the neuroscience and oncology domain. Jazz Pharmaceuticals plays a crucial role in driving innovation and growth in the market by substantially investing in the clinical development of ASD therapeutics.
Novartis AG
Novartis AG, a Swiss multinational pharmaceutical corporation, significantly contributes to autism spectrum disorder therapeutics market growth, by participating in strategic collaborations to advance the understanding and treatment of ASD. Such partnerships also accelerate the development of effective therapies.
Johnson & Johnson Services, Inc.
Johnson & Johnson pharmaceutical drug division Johnson & Johnson Innovative Medicine heavily invests in research and development for neurological disorders including autism spectrum disorder. Its established portfolio of psychiatric medications makes it one of the leading players in the market.
Other key players in the market include Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
Key Questions Answered in the Autism Spectrum Disorder Therapeutics Market Report
Autism Spectrum Disorder Therapeutics Market Overview
Autism spectrum disorder (ASD) is a neurological development disability characterized by conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. This neurological and developmental disorder can begin in infancy and last throughout adulthood throughout a person’s life. It can be diagnosed based on behavioural patterns. ASD treatments are focused on reducing the factors that interfere with an individual’s orderly functioning. Some of the drugs approved by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.
The autism spectrum disorder therapeutics market is affected by the growing number of patients and the increasing awareness regarding the disease. The rising governmental initiatives are also expected to encourage research in this area. Further, rapid technological advancements in medicine are likely to favor market growth during the forecast period. Moreover, the adoption of behavioral therapies to overcome the communication gap in such patients is poised to aid the market expansion.
Autism Spectrum Disorder Therapeutics Market Growth Drivers
Rising Number of Pipeline Drugs Expected to Propel Market Growth
The forecast period is expected to witness rising development of drugs to treat autism spectrum disorder. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the market growth. For instance, in 2023, STALICLA, a Swiss clinical-stage biotech company announced the completion of the phase 1b trials for STP1. The trials will allow the application of the company’s precision medicine discovery platform in ASD. The increasing research and development activities associated with autism spectrum disorder are expected to result in the introduction of new and effective treatment options, which are set to elevate the market value.
Growth in Clinical Trials to Meet Rising Autism Spectrum Disorder Therapeutics Market Demand
In March 2024, a clinical-stage biopharmaceutical company based in Israel, SciSparc Ltd., announced the dosing of the first patient in the SCI-210 clinical trial, a randomized, controlled, double-blind clinical trial for pediatric patients with autism spectrum disorder. SCI-210 treatment is a combination of CannAmide™ (palmitoylethanolamide-based tablets) and cannabidiol-rich oil (CBD). The clinical trial, which will enroll 60 children, aims to assess the safety, efficacy, and tolerability of SCI-210 for the treatment of ASD in comparison to CBD monotherapy. The surge in clinical trials, supported by substantial investment from the leading pharmaceutical companies, is anticipated to significantly contribute to the market growth.
Autism Spectrum Disorder Therapeutics Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Advancement in Diagnostic Tools
The rising advancement in diagnostic tools and techniques that enable earlier detection of autism spectrum disorder is a major trend that stimulates the demand for the therapeutics market. Further, increased implementation of screening programs, particularly in schools and pediatric practices, is resulting in early diagnosis and timely intervention._x000D_
Development of Behavioral Therapies
The rising focus on the development of behavioral therapies is a major market trend. Behavioral therapies including applied behavior analysis (ABA) and cognitive-behavioral therapy (CBT) are increasingly being integrated into treatment plans and are poised to boost the autism spectrum disorder therapeutics market share._x000D_
Rising Adoption of Telemedicine and Digital Health Platforms
The market is experiencing a rising adoption of telemedicine and digital health platforms which has expanded access to care for individuals with autism spectrum disorder, particularly those living in underserved areas. The increasing remote access to care is expected to augment the market demand in the forecast period._x000D_
Increased Awareness Campaigns
Increased public campaigns and advocacy efforts are leading to greater acceptance of autism spectrum disorder, which is resulting in early diagnosis of the affected patients. In addition, advocacy groups and several foundations are offering considerable funding and support for ASD research and treatment development, which directly impacts the market dynamics.
Autism Spectrum Disorder Therapeutics Market Segmentation
Autism Spectrum Disorder Therapeutics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Autistic Disorder
- Asperger’s Syndrome
- Pervasive Development Disorder (PDD)
- Others
- Antipsychotic Drugs
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Stimulants
- Sleep Medications
- Others
- Child
- Adult
- Oral
- Parenteral
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on treatment, the market is segmented into antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs), stimulants, and sleep medications, among others. These medications help in treating different aspects associated with the disorder, ranging from managing core symptoms to treating comorbid conditions. The antipsychotic drugs segment covers a significant market share owing to their efficacy in managing severe behavioral issues such as aggression, irritability, and self-injurious behaviors, which are common in individuals affected by the condition.
Autism Spectrum Disorder Therapeutics Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is expected to hold a significant share of the market during the forecast period, supported by the increased number of autism spectrum disorder cases in the region. The market is also supported by the presence of a favorable regulatory environment. For example, the United States Food and Drug Administration (FDA) authorized the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD) in 2021.
The region is also characterised by research and development in the field of autism spectrum disorder which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the United States, supports research focused on the treatment of autism spectrum disorder and related disorders.
Leading Players in the Autism Spectrum Disorder Therapeutics Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Abbvie Inc.
American pharmaceutical company AbbVie Inc. is involved in research and development (R&D) efforts to create medications for autism spectrum disorder. The company's robust portfolio of neurological and psychiatric therapeutics and its strong R&D capabilities position it as a significant player in the market.
Jazz Pharmaceuticals
This global biopharmaceutical company specializes in developing treatments in the neuroscience and oncology domain. Jazz Pharmaceuticals plays a crucial role in driving innovation and growth in the market by substantially investing in the clinical development of ASD therapeutics.
Novartis AG
Novartis AG, a Swiss multinational pharmaceutical corporation, significantly contributes to autism spectrum disorder therapeutics market growth, by participating in strategic collaborations to advance the understanding and treatment of ASD. Such partnerships also accelerate the development of effective therapies.
Johnson & Johnson Services, Inc.
Johnson & Johnson pharmaceutical drug division Johnson & Johnson Innovative Medicine heavily invests in research and development for neurological disorders including autism spectrum disorder. Its established portfolio of psychiatric medications makes it one of the leading players in the market.
Other key players in the market include Curemark LLC, Bristol Myers Squibb Co., Axial Therapeutics, Q BioMed Inc., PaxMedica, Otsuka Pharmaceutical, Stalicla SA, and Zynerba Pharmaceuticals, Inc.
Key Questions Answered in the Autism Spectrum Disorder Therapeutics Market Report
- What was the autism spectrum disorder therapeutics market value in 2024?
- What is the autism spectrum disorder therapeutics market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on disease type?
- What is the market breakup based on treatment type?
- What is the market breakup by age group?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the autism spectrum disorder therapeutics market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of autism spectrum disorder affect the market landscape?
- What are the major autism spectrum disorder therapeutics market trends?
- Which disease type will dominate the market share?
- Which treatment type is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which age group is projected to contribute to the highest market growth?
- Who are the key players involved in the autism spectrum disorder therapeutics market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Autism Spectrum Disorder Therapeutics Market Overview: 8 Major Market
- 3.1 Autism Spectrum Disorder Therapeutics Market Historical Value (2018-2024)
- 3.2 Autism Spectrum Disorder Therapeutics Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Autism: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Autism Spectrum Disorder Therapeutics Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Autism Spectrum Disorder Therapeutics Market Landscape: 8 Major Market*
- 8.1 Autism Spectrum Disorder Therapeutics Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Autism Spectrum Disorder Therapeutics Market: Product Landscape
- 8.2.1 Analysis by Disease Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Age Group
- 8.2.4 Analysis by Route of Administration
- 9 Autism Spectrum Disorder Therapeutics Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Autism Spectrum Disorder Therapeutics: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Autism Spectrum Disorder Therapeutics Market Segmentation: 8 Major Market
- 12.1 Autism Spectrum Disorder Therapeutics Market by Disease Type
- 12.1.1 Market Overview
- 12.1.2 Autistic Disorder
- 12.1.3 Asperger’s Syndrome
- 12.1.4 Pervasive Development Disorder (PDD)
- 12.1.5 Others
- 12.2 Autism Spectrum Disorder Therapeutics Market by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Antipsychotic Drugs
- 12.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 12.2.4 Stimulants
- 12.2.5 Sleep Medications
- 12.2.6 Others
- 12.3 Autism Spectrum Disorder Therapeutics Market by Age Group
- 12.3.1 Market Overview
- 12.3.2 Child
- 12.3.3 Adult
- 12.4 Autism Spectrum Disorder Therapeutics Market by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Oral
- 12.4.3 Parenteral
- 12.5 Autism Spectrum Disorder Therapeutics Market by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Autism Spectrum Disorder Therapeutics Market (218-2034)
- 13.1 United States Autism Spectrum Disorder Therapeutics Market Historical Value (2018-2024)
- 13.2 United States Autism Spectrum Disorder Therapeutics Market Forecast Value (2025-2034)
- 13.3 United States Autism Spectrum Disorder Therapeutics Market by Disease Type
- 13.3.1 Market Overview
- 13.3.2 Autistic Disorder
- 13.3.3 Asperger’s Syndrome
- 13.3.4 Pervasive Development Disorder (PDD)
- 13.3.5 Others
- 13.4 United States Autism Spectrum Disorder Therapeutics Market by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Antipsychotic Drugs
- 13.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 13.4.4 Stimulants
- 13.4.5 Sleep Medications
- 13.4.6 Others
- 13.5 United States Autism Spectrum Disorder Therapeutics Market by Age Group
- 13.5.1 Market Overview
- 13.5.2 Child
- 13.5.3 Adult
- 13.6 United States Autism Spectrum Disorder Therapeutics Market by Route of Administration
- 13.6.1 Market Overview
- 13.6.2 Oral
- 13.6.3 Parenteral
- 14 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market (218-2034)
- 14.1 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Disease Type
- 14.3.1 Market Overview
- 14.3.2 Autistic Disorder
- 14.3.3 Asperger’s Syndrome
- 14.3.4 Pervasive Development Disorder (PDD)
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Antipsychotic Drugs
- 14.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 14.4.4 Stimulants
- 14.4.5 Sleep Medications
- 14.4.6 Others
- 14.5 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Age Group
- 14.5.1 Market Overview
- 14.5.2 Child
- 14.5.3 Adult
- 14.6 EU-4 and United Kingdom Autism Spectrum Disorder Therapeutics Market by Route of Administration
- 14.6.1 Market Overview
- 14.6.2 Oral
- 14.6.3 Parenteral
- 15 Japan Autism Spectrum Disorder Therapeutics Market
- 15.1 Japan Autism Spectrum Disorder Therapeutics Market Historical Value (2018-2024)
- 15.2 Japan Autism Spectrum Disorder Therapeutics Market Forecast Value (2025-2034)
- 15.3 Japan Autism Spectrum Disorder Therapeutics Market by Disease Type
- 15.3.1 Market Overview
- 15.3.2 Autistic Disorder
- 15.3.3 Asperger’s Syndrome
- 15.3.4 Pervasive Development Disorder (PDD)
- 15.3.5 Others
- 15.4 Japan Autism Spectrum Disorder Therapeutics Market by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Antipsychotic Drugs
- 15.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 15.4.4 Stimulants
- 15.4.5 Sleep Medications
- 15.4.6 Others
- 15.5 Japan Autism Spectrum Disorder Therapeutics Market by Age Group
- 15.5.1 Market Overview
- 15.5.2 Child
- 15.5.3 Adult
- 15.6 Japan Autism Spectrum Disorder Therapeutics Market by Route of Administration
- 15.6.1 Market Overview
- 15.6.2 Oral
- 15.6.3 Parenteral
- 16 India Autism Spectrum Disorder Therapeutics Market
- 16.1 India Autism Spectrum Disorder Therapeutics Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Autism Spectrum Disorder Therapeutics Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Autism Spectrum Disorder Therapeutics Market by Disease Type
- 16.3.1 Market Overview
- 16.3.2 Autistic Disorder
- 16.3.3 Asperger’s Syndrome
- 16.3.4 Pervasive Development Disorder (PDD)
- 16.3.5 Others
- 16.4 India Autism Spectrum Disorder Therapeutics Market by Treatment Type
- 16.4.1 Market Overview
- 16.4.2 Antipsychotic Drugs
- 16.4.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 16.4.4 Stimulants
- 16.4.5 Sleep Medications
- 16.4.6 Others
- 16.5 India Autism Spectrum Disorder Therapeutics Market by Age Group
- 16.5.1 Market Overview
- 16.5.2 Child
- 16.5.3 Adult
- 16.6 India Autism Spectrum Disorder Therapeutics Market by Route of Administration
- 16.6.1 Market Overview
- 16.6.2 Oral
- 16.6.3 Parenteral
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Abbvie Inc
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Jazz Pharmaceuticals
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Johnson & Johnson Services, Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Curemark LLC
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Bristol Myers Squibb Co .
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Axial therapeutics
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Q BioMed Inc .
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 PaxMedica
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Otsuka Pharmaceutica
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 Stalicla SA
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 Zynerba Pharmaceuticals, Inc .
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 24 Autism Spectrum Disorder Therapeutics Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
